Tanabe Pharma America, Inc.

3 in Phase 3

Quick facts

Phase 3 pipeline

MT-7117 · Cardiovascular
MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.
MT-7117 high dose · Cardiovascular
MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.
MT-7117 low dose · Cardiovascular / Pulmonary Hypertension
MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Tanabe Pharma America, Inc.

What is Tanabe Pharma America, Inc.'s pipeline?

Tanabe Pharma America, Inc. has 3 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include MT-7117, MT-7117 high dose, MT-7117 low dose.

Sector hub: All tracked pharma companies